Profile

Cover photo
Amarantus BioScience Holdings, Inc.
38 followers|18,221 views
AboutPosts

Stream

 
Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), announced the publication of data on its next generation sequencing (NGS) molecular diagnostic test for multiple sclerosis, MSPrecise®. The paper entitled, "MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing," has been published in the Elsevier journal GENE. "Given the early misdiagnoses that often occur with multiple sclerosis, physicians have an increasing need for new methods to accurately diagnose their patients," said Colin Bier, Chief Development Officer of Amarantus Diagnostics. "MSPrecise scoring is a powerful approach to aid clinicians in this task. In this study completed in 2013 and now reported in 'GENE,' there is an overall MSPrecise accuracy of 84% in identifying RRMS patients or patients that will develop RRMS, which represents a huge benefit to physicians. In early 2015, Amarantus reported data from a later study that showed a significant increase in the accuracy of MSPrecise when adding oligoclonal banding (OCB) to the algorithm. We intend to publish those data combining MSPrecise and OCB in the near future." Read the press release available here for additional details and information: http://bit.ly/1h4Tx3J
Results from this study were not combined with oligoclonal banding (OCB) -. - MSPrecise performs well in identifying MS among a broad cohort of potential neurological diseases -. SAN FRANCISCO and GENEVA, July 29, 2015 (GLOBE NEWSWIRE) -- Amarantus Diagnostics, a neurology-focused diagnostics ...
1
Add a comment...
 
Amarantus Diagnostics a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), announced today that it has established a Strategic Advisory Committee (SAC). Three seasoned, results-driven life science and healthcare industry leaders with expertise in commercializing molecular diagnostics have been appointed to focus on advancing and deriving the full value of the company’s diagnostics business: Philippe Goix, Ph.D., MBA; Steven T. Guillen, MBA; and Brian E. Ward, Ph.D. Gerald E. Commissiong, President & CEO of Amarantus Bioscience Holdings stated, “This team of advisors has a proven track record of strategically extracting commercial profitability by advancing companies and their products through a robust commercialization pathway. These skills will be instrumental as we mature the neuro-diagnostics business into a powerhouse in the life sciences industry.” Read the full press release for additional details an information: http://bit.ly/1JKouRA
Advisors Bring Over 30 Years of Expertise in Successfully Commercializing Molecular Diagnostics Companies. SAN FRANCISCO and GENEVA, July 27, 2015 (GLOBE NEWSWIRE) -- Amarantus Diagnostics, a neurology-focused diagnostics company developing diagnostic tests for multiple sclerosis and Alzheimer's ...
1
Add a comment...
 
In a guest blog, Dr. Paula T. Trzepacz, Clinical Professor of Psychiatry, Indiana University School of Medicine, Indianapolis, IN and member of Amarantus' Clinical Advisory Board, discusses the encouraging LymPro Test data presented by Amarantus today at the 2015 Alzheimer's Association International Conference (AAIC). Dr. Trzepacz states that an alternative blood biomarker is needed to enhance the clinical diagnosis of AD and highlights the Lympro Test as a blood biomarker under investigation that holds promise as an adjunctive biomarker for AD diagnosis; which also addresses a unique aspect of AD brain neuropathology, cell cycle dysfunction. Read her full blog available here: http://bit.ly/1gP59aQ
Alzheimer’s disease (AD) has become a household word because it afflicts approximately 5 million older Americans with projections to afflict over 7 million by 2030. AD causes gradual disability through progressive deterioration of the brain. It is often not detected in its earlier stages when lifestyle changes and some medications could be started and can... Read More ...
1
Add a comment...
 
Amarantus Diagnostics today reported positive results on the accuracy of the LymPro Test, its blood-based diagnostic assay for Alzheimer's disease, to discriminate between subjects with clinically diagnosed AD versus healthy controls at the Alzheimer's Association International Conference (AAIC) being held July 18-23, 2015, in Washington, DC. Results from a blinded, multi-center LP-002 clinical study for LymPro blood diagnostic for Alzheimer's disease confirmed that LymPro had comparable AD diagnostic accuracy to the the study's reference standard of clinical diagnosis by dementia experts. The Company also confirmed LymPro's Fit-for-Purpose use in Alzheimer's clinical trials. Read the full release here: http://bit.ly/1JyMMht
Press Releases. Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer's Association International ...
1
Add a comment...
 
Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer's Association International Conference(R) http://bit.ly/1gOOsMM
Press Releases. Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer's Association International ...
1
Add a comment...
 
A concussion results in temporary loss of brain function, affecting memory, judgement, reflexes, speech, balance and coordination. http://bit.ly/1JbOVDG
1
Add a comment...
Have them in circles
38 people
Ana Nassaney's profile photo
Tatiana Zuluaga's profile photo
Rachel Francine's profile photo
Thomas Steele's profile photo
Struggling To Focus's profile photo
Laura Anthony, Esq.'s profile photo
tahir jabbar mir's profile photo
Keith Rohr's profile photo
Christopher Scott's profile photo
 
Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), announced the publication of data on its next generation sequencing (NGS) molecular diagnostic test for multiple sclerosis, MSPrecise®. The paper entitled, "MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing," has been published in the Elsevier journal GENE. "Given the early misdiagnoses that often occur with multiple sclerosis, physicians have an increasing need for new methods to accurately diagnose their patients," said Colin Bier, Chief Development Officer of Amarantus Diagnostics. "MSPrecise scoring is a powerful approach to aid clinicians in this task. In this study completed in 2013 and now reported in 'GENE,' there is an overall MSPrecise accuracy of 84% in identifying RRMS patients or patients that will develop RRMS, which represents a huge benefit to physicians. In early 2015, Amarantus reported data from a later study that showed a significant increase in the accuracy of MSPrecise when adding oligoclonal banding (OCB) to the algorithm. We intend to publish those data combining MSPrecise and OCB in the near future." Read the press release available here for additional details and information: http://bit.ly/1h4Tx3J
Results from this study were not combined with oligoclonal banding (OCB) -. - MSPrecise performs well in identifying MS among a broad cohort of potential neurological diseases -. SAN FRANCISCO and GENEVA, July 29, 2015 (GLOBE NEWSWIRE) -- Amarantus Diagnostics, a neurology-focused diagnostics ...
1
Add a comment...
 
Click here to learn more about our therapeutics pipeline, which includes Eltoprazine, ESS and MANF: http://bit.ly/1JsAFCs
1
Add a comment...
 
Amarantus Diagnostics today reported positive results on the accuracy of the LymPro Test, its blood-based diagnostic assay for Alzheimer's disease, to discriminate between subjects with clinically diagnosed AD versus healthy controls at the Alzheimer's Association International Conference (AAIC) being held July 18-23, 2015, in Washington, DC. Results from a blinded, multi-center LP-002 clinical study for LymPro blood diagnostic for Alzheimer's disease confirmed that LymPro had comparable AD diagnostic accuracy to the the study's reference standard of clinical diagnosis by dementia experts. The Company also confirmed LymPro's Fit-for-Purpose use in Alzheimer's clinical trials. Read the full release here: http://bit.ly/1JyMMht
Press Releases. Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer's Association International ...
1
Add a comment...
 
Amarantus Diagnostics today reported positive results on the accuracy of the LymPro Test, its blood-based diagnostic assay for Alzheimer's disease, to discriminate between subjects with clinically diagnosed AD versus healthy controls at the Alzheimer's Association International Conference (AAIC) being held July 18-23, 2015, in Washington, DC. Results from a blinded, multi-center LP-002 clinical study for LymPro blood diagnostic for Alzheimer's disease confirmed that LymPro had comparable AD diagnostic accuracy to the the study's reference standard of clinical diagnosis by dementia experts. The Company also confirmed LymPro's Fit-for-Purpose use in Alzheimer's clinical trials. Read the full release here: http://bit.ly/1JyMMht
Press Releases. Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer's Association International ...
1
Add a comment...
 
How does Parkinson's disease affect the body? Learn about the physical and mental effects, as well as the progression of the disease: http://bit.ly/1JbPoWJ
1
Add a comment...
 
In his blog for HuffPost Healthy Living, Allan S. Vann discusses the difficulties as a caregiver following his wife's Alzheimer's diagnosis. Read more: http://huff.to/1JszBP1
1
Add a comment...
People
Have them in circles
38 people
Ana Nassaney's profile photo
Tatiana Zuluaga's profile photo
Rachel Francine's profile photo
Thomas Steele's profile photo
Struggling To Focus's profile photo
Laura Anthony, Esq.'s profile photo
tahir jabbar mir's profile photo
Keith Rohr's profile photo
Christopher Scott's profile photo
Contact Information
Contact info
Phone
(408) 737-2734
Email
Address
c/o Janssen Labs @ QB3 953 Indiana Street San Francisco, CA 94107
c/o ICS Corporate Services SA 29 quai du Mont Blanc CH-1201 Geneva Switzerland
Story
Tagline
Amarantus (OTCQX: AMBS) is a biotechnology company developing new treatments for disorders of the brain. Join us to raise awareness! #C4CT
Introduction
Amarantus BioScience Holdings, Inc. (OTCQX: AMBS) is a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis.